Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
NKTX Nkarta
5.730-0.070-1.21%
Trading Session
02/03 09:44 ET
High
5.805
Open
5.720
Turnover
206.73K
Low
5.620
Pre Close
5.800
Volume
36.26K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research
LXRX, PGNY and ANGI Are Among After Hour Movers
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of "Moderate Buy" by Brokerages
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has received an average rating of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst
Nkarta Promotes David Shook to Chief Medical Officer
Nkarta: Promotes David R. Shook, M.D., to Chief Medical Officer
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most
Nkarta, Inc. Forecasted to Post FY2024 Earnings of ($3.17) Per Share (NASDAQ:NKTX)
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) – Investment analysts at Oppenheimer reduced their FY2024 earnings per share (EPS) estimates for shares of Nkarta in a report released on Thursday, December
Oppenheimer Lowers Nkarta (NASDAQ:NKTX) to Market Perform
Oppenheimer lowered shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports. A number of othe
Nkarta (NASDAQ:NKTX) Downgraded by Oppenheimer
Oppenheimer downgraded shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note released on Thursday morning, Marketbeat reports. A number o
Market Prospects For Some Biotechs May Be Limited -- Market Talk
12:18 ET - Oppenheimer says it downgraded cell therapy names Fate Therapeutics, Celularity and Nkarta because it feels that in the treatment of diseases like lymphoma and myeloma, NK-cell therapies ar
Company Overview
More
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
CEO： Mr. Paul J. Hastings
Market： NASDAQ
Listing Date： 07/10/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet